Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOVUE-250 vs HEXABRIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Iopamidol is a nonionic, water-soluble iodinated radiographic contrast agent that attenuates X-rays, thereby providing contrast enhancement in imaging studies. Its mechanism of action is physical rather than pharmacological, as it does not have inherent biological activity.
Hexabrix is an ionic, high-osmolar iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures. Its mechanism is physical rather than pharmacological, based on iodine's atomic number and density.
Intravascular use for computed tomography (CT) of the head and body,Intrathecal use for lumbar, thoracic, and cervical myelography,Coronary arteriography and ventriculography,Peripheral arteriography,Excretory urography,Visceral angiography
Intravascular administration for arteriography, venography, and computed tomography (CT) imaging,Intrathecal administration for myelography (lumbar, thoracic, cervical, and total columnar myelography),Off-label: Arthrography, hysterosalpingography, and ductography
Intravenous administration of 50-150 m L (12-37 g iodine) for CT imaging; intra-arterial administration of 10-80 m L (2.5-20 g iodine) for angiography; dose depends on procedure and patient weight.
Intravenous: 0.3-0.6 m L/kg (maximum 100 m L) for urography; 40-80 m L for CT enhancement.
Terminal elimination half-life: 1.5-2 hours (normal renal function); clinically, half-life prolonged in renal impairment
Terminal elimination half-life: 1.5–2 hours in adults (prolonged in renal impairment; up to 30 hours in severe CKD)
Iopamidol is not metabolized. It is excreted unchanged by glomerular filtration, primarily via the kidneys. In patients with normal renal function, 90% or more of the administered dose is eliminated in the urine within 24 hours.
Not metabolized; eliminated unchanged via glomerular filtration by the kidneys.
Primarily renal: 90-95% unchanged in urine within 24 hours; biliary/fecal: <5%
Renal: 95% unchanged via glomerular filtration; Biliary: <5%; Fecal: <1%
<5% bound; primarily to albumin
Negligible (<5%); no specific binding proteins
0.2-0.3 L/kg; reflects distribution in extracellular fluid (does not cross intact blood-brain barrier)
0.3–0.4 L/kg (confined to extracellular space; does not cross intact blood-brain barrier)
Intravascular: 100%; oral: negligible (<1%)
Intravenous/Intra-arterial: 100%; Oral: 0% (not absorbed)
e GFR <30 m L/min/1.73m²: avoid use or use minimal dose with adequate hydration; e GFR 30-59: consider lowest effective dose and ensure hydration; no specific dose reduction for e GFR ≥60.
Contraindicated in patients with GFR <30 m L/min/1.73m². For GFR 30-59 m L/min, reduce dose by 50% and ensure adequate hydration.
No specific Child-Pugh based dose modifications; use with caution in severe hepatic impairment due to potential contrast-induced nephropathy risk.
No specific Child-Pugh based adjustments; use caution in severe hepatic impairment due to risk of hepatorenal syndrome.
Children: 1-2 m L/kg (250-500 mg iodine/kg) intravenously for CT, not to exceed adult dose; adjust for body weight and procedure.
Intravenous: 0.5-1 m L/kg (maximum 2 m L/kg) for urography; not recommended for neonates due to risk of acute renal failure.
Elderly patients: use lowest effective dose; ensure adequate hydration; monitor renal function closely due to age-related decline and increased risk of nephropathy.
Reduce dose by 25-50% in patients >70 years; maintain hydration and monitor renal function.
Intrathecal administration may result in neurotoxicity including seizures, meningitis, and arachnoiditis. Inadvertent intravascular injection during intrathecal administration may cause serious adverse reactions.
Risk of severe, life-threatening adverse reactions including anaphylaxis, cardiovascular collapse, and seizures. Use only when diagnostic information is essential. Resuscitative equipment and trained personnel must be immediately available.
Do not use for myelography if procedures are contraindicated,Risk of serious adverse reactions in patients with impaired renal function, including acute renal failure,Risk of cardiorespiratory arrest, anaphylactic shock, and other severe allergic reactions,Potential for thyroid storm in patients with hyperthyroidism,Caution in patients with pheochromocytoma, sickle cell disease, and multiple myeloma
Risk of acute renal failure, particularly in patients with pre-existing renal impairment, diabetes, or dehydration. Caution in patients with cardiovascular disease, asthma, or known hypersensitivity. Avoid extravasation. Thyroid function tests may be affected. Ensure adequate hydration before and after administration.
History of severe allergic reaction to iopamidol or any component of the formulation,Intrathecal administration in patients with thrombophlebitis, infection, or malignancy at the injection site,Severe renal impairment (anuria, oliguria) unless the benefits outweigh the risks,Patients with a history of grand mal seizures, or those on drugs that lower seizure threshold, for intrathecal use
Absolute: Known hypersensitivity to iodinated contrast media, overt thyrotoxicosis, anuria or severe oliguria due to renal disease. Relative: Myeloma, pheochromocytoma, sickle cell disease, pregnancy, and concomitant use of nephrotoxic drugs.
No known food interactions. However, ensure adequate hydration before and after the procedure. Avoid alcohol 24 hours prior as it may increase risk of dehydration.
No specific food interactions. Maintain adequate hydration; alcohol should be avoided as it may increase dehydration risk.
ISOVUE-250 (iopamidol) is an iodinated contrast agent. In pregnant women, exposure to ionizing radiation from procedures involving iodinated contrast should be minimized. Iodinated contrast agents cross the placenta and may produce transient neonatal hypothyroidism if used in the third trimester. However, data from clinical studies are insufficient to determine a definitive teratogenic risk. First trimester exposure has not been associated with major congenital malformations, but caution is warranted due to potential fetal hypothyroidism with prolonged use near term.
HEXABRIX (ioxaglate meglumine and ioxaglate sodium) is an iodinated contrast agent. In animal studies, no teratogenic effects were observed. In humans, there is no evidence of fetal harm from diagnostic doses, though theoretical risks from free iodide exist, especially in the third trimester. The American College of Radiology recommends use only if clearly needed, with minimal dose.
Limited data suggest that iopamidol is excreted into human breast milk in very small amounts. The milk-to-plasma (M/P) ratio is not specifically reported for iopamidol, but for similar iodinated contrast agents, the M/P ratio is low (<0.2). The amount of iodine transferred to the infant is negligible and unlikely to cause adverse effects. However, the American College of Radiology and other guidelines recommend that breastfeeding may be continued without interruption after receiving iodinated contrast, although some advise discarding milk for 12-24 hours if the mother is concerned.
Iodinated contrast agents are excreted into breast milk in very small amounts (<0.01% of maternal dose). The M/P ratio is not established. Breastfeeding can continue without interruption, but some sources suggest discarding milk for 12-24 hours if desired.
Pregnancy does not require dose adjustments for ISOVUE-250. The dose should be based on the diagnostic procedure and patient weight. However, because of potential fetal hypothyroidism risk from free iodide, alternative imaging modalities without iodinated contrast should be considered if possible, especially in the third trimester.
No dose adjustment is recommended for pregnancy. However, use the lowest necessary dose to achieve diagnostic image. Renal function may be altered in pregnancy; ensure adequate hydration to prevent contrast-induced nephropathy.
ISOVUE-250 (iopamidol 51%) is a nonionic, low-osmolality iodinated contrast medium used for angiography, urography, and CT enhancement. In patients with renal impairment (e GFR <30 m L/min), consider N-acetylcysteine prophylaxis and hydration to reduce risk of contrast-induced nephropathy. Monitor for delayed hypersensitivity reactions, which can occur up to 7 days post-administration. Use caution in patients with pheochromocytoma; pre-treat with alpha-blockers. Shellfish allergy is not a contraindication; true iodine allergy is rare. For intrathecal use, avoid concurrent neurotoxic drugs and ensure patient hydration.
HEXABRIX (ioxaglate meglumine and ioxaglate sodium) is a low-osmolar, ionic, dimeric contrast medium used for intravascular administration. It has lower osmolality than conventional ionic monomers, reducing the risk of contrast-induced nephropathy and hemodynamic disturbances. Ensure adequate hydration before and after administration. Caution in patients with renal impairment, diabetes, multiple myeloma, or prior contrast reactions. Do not mix with other drugs. Monitor for delayed hypersensitivity reactions.
Inform your doctor if you have kidney disease, diabetes, or are taking metformin; metformin may need to be stopped temporarily.,Tell your doctor about all allergies, especially to medications or iodine.,You may feel warmth, flushing, or a metallic taste when the contrast is injected; this is normal.,Drink plenty of water before and after the procedure to help flush the contrast from your body.,Report any symptoms like hives, itching, difficulty breathing, or swelling of the face/mouth immediately.,If you are pregnant or breastfeeding, discuss potential risks with your doctor.
Inform your doctor if you have kidney disease, diabetes, or any allergies, especially to contrast agents.,Drink plenty of fluids before and after the procedure to stay hydrated.,You may experience a warm sensation or metallic taste during injection; this is normal.,Report any symptoms like hives, itching, difficulty breathing, or swelling after the scan.,If you take metformin, you may need to stop it temporarily as directed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOVUE-250 vs HEXABRIX, answered by our medical review team.
ISOVUE-250 is a Contrast Media that works by Iopamidol is a nonionic, water-soluble iodinated radiographic contrast agent that attenuates X-rays, thereby providing contrast enhancement in imaging studies. Its mechanism of action is physical rather than pharmacological, as it does not have inherent biological activity.. HEXABRIX is a Contrast Media that works by Hexabrix is an ionic, high-osmolar iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures. Its mechanism is physical rather than pharmacological, based on iodine's atomic number and density.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOVUE-250 and HEXABRIX depend on the specific clinical indication. These are both Contrast Media agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOVUE-250 is: Intravenous administration of 50-150 m L (12-37 g iodine) for CT imaging; intra-arterial administration of 10-80 m L (2.5-20 g iodine) for angiography; dose depends on procedure and patient weight.. The standard adult dose of HEXABRIX is: Intravenous: 0.3-0.6 m L/kg (maximum 100 m L) for urography; 40-80 m L for CT enhancement.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOVUE-250 and HEXABRIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOVUE-250 is classified as Category C. ISOVUE-250 (iopamidol) is an iodinated contrast agent. In pregnant women, exposure to ionizing radiation from procedures involving iodinated contrast should be minimized. Iodinated. HEXABRIX is classified as Category C. HEXABRIX (ioxaglate meglumine and ioxaglate sodium) is an iodinated contrast agent. In animal studies, no teratogenic effects were observed. In humans, there is no evidence of feta. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.